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Abstract 
Purpose of review 
There is growing consensus that genomic assays provide useful complementary information 
to clinicopathological features in oestrogen receptor (ER)-positive breast cancers. Here, 
ongoing research with multigene tests used for postmenopausal breast cancer and new 
emerging prognostic and predictive markers for pre- and postmenopausal women are 
summarised. 
Recent findings 
Results of the TAILORx trial have shown that women with an intermediate risk score do not 
benefit from adjuvant chemotherapy. Prosgina has been further investigated in a 
contemporary patient population in postmenopausal women and its use has been extended 
for premenopausal women. The EndoPredict was extensively used in decision-impact studies 
showing that its use can potentially reduce the need for adjuvant chemotherapy. Several new 
genomic assays have been developed, with some of them showing promising use for women 
with early ER-positive breast cancer.  
Summary 
New areas of research for prediction of recurrence and risk stratification involve the 
development of immune gene signatures that carry modest but significant prognostic value. 
The recent expansion of high-throughput technology platforms including circulating tumour 
DNA/RNA and microRNA offer new opportunities to improve prediction models, particularly 
in women with ER-negative disease and premenopausal women. Genomic assays have clearly 
improved prognostication of early ER-positive breast cancer but it is clear that standard 
clinicopathological parameters are still very important when identifying patient for adjuvant 
chemotherapy. 
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Introduction 
Breast cancer is a heterogeneous disease and prediction of risk of recurrence depends on 
several clinicopathological factors: tumour size, histologic grade, lymph node involvement, 
and expression of both the oestrogen (ER) and on HER2 protein overexpression or gene 
amplification (or both) [1]. Traditionally these factors are used to determine what adjuvant 
treatment is necessary for early stage breast cancer. In most cases, patients with ER-positive 
breast cancer are offered endocrine therapy, and patients with HER2-positive tumours are 
offered both chemotherapy and anti HER2 therapies. However, determining which ER-
positive, HER2-negative patients should be offered chemotherapy is a more complex 
question. Furthermore, there are no clinically useful prognostic signatures for ER-negative 
breast cancer, and drug-specific treatment response predictors also remain elusive. 
 
Several multigene prognostic tests have been developed over the past two decades to 
improve and guide clinical treatment decisions with regard to systemic chemotherapy. In 
particular, these tests have been developed to improve prognostication of early-stage breast 
cancer in addition to clinicopathological features within the first five years of diagnosis.  
Oncotype DX [2], MammaPrint [3] and Genomic Grade Index [4], which are first-generation 
tests, are more accurate to predict specifically recurrence within the first 5 years after 
diagnosis than in later years. This has become a limitation with the availability of effective 
extended adjuvant endocrine therapies. Newer test, such as Prosigna [5], EndoPredict [6], 
Breast Cancer Index [7], possess better prognostic value for late recurrences while also 
remaining highly predictive of early relapse. An important aspect of genomic assays is the 
distinction between utility of these tests for prognosis (recurrence) and for prediction 
(treatment response). Some argue that genomic assays need to show distinctive predictive 
utility to determine who needs chemotherapy, with data deriving from prospective, 
randomised trials. However, treatment effects need to be assessed in terms of absolute 
benefits and thus a genomic test that is highly prognostic for recurrence (accurate 
stratification into low or high risk groups) is still highly predictive of the absolute benefit of 
treatment.  
 
Therefore, the accurate stratification of patients into low and high risk groups is an important 
clinical questions since that determines, along with clinicopathological features, who should 
receive adjuvant chemotherapy. Another important aspect to consider is the presence of an 
intermediate risk group with some of the genomic assays. This risk group includes patients 
with an elevated risk of recurrence but at a level of clinical uncertainty because of lack of clear 
evidence of chemotherapy benefit. This review discuss several new findings with respect to 
risk stratification using genomic assays, in particular for postmenopausal women.  
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Clinicopathological features 
Prognosis using clinicopathological features is clinically still important and should not be 
forgotten. It has been shown that genomic assays that incorporate clinical features perform 
substantially better in terms of prognosis than purely molecular assays. One of the most 
important clinical factor is lymph node involvement, followed by tumour size and grade [8, 
9]. Despite many advances in the development of genomic assays, clinical factors continue to 
remain of importance when determining prognosis in early breast cancer. 
More than 50% of recurrence in women with ER-positive disease occur 5 years after initial 
diagnosis. The use of clinicopathological features has been used to determine who is at risk 
of developing a late distant recurrence. An overview analysis of over 60000 women with ER-
positive disease who received 5 years of endocrine therapy and remained disease free at 5 
years reported the subsequent risk of distant recurrence [10]. Even in patients with small 
tumours and node negative disease, the estimated risk of distant recurrence between years 
5 and 20 was 10% for those with low, 13% for those with intermediate, and 17% for those 
with high grades, respectively. The data were presented as risk categories mainly using 
tumour size categories (e.g. T1, T2), limiting precise estimates of risk for individual patients. 
Furthermore, the analysis included mainly a tamoxifen-treated population, which did not 
allow assessment of possible differences between tamoxifen and aromatase inhibitors (AIs) 
with regard to long-term risk. 
 
More recently, we reported on the use of clinicopathological features for the prediction of 
late distant recurrences in a combined dataset of two large clinical trials, which compared an 
aromatase inhibitor with tamoxifen [11]. We developed a simple prognostic tool that 
stratifies patient into low, intermediate, and high risk of developing a late distant recurrence, 
with distinctively different 5-10 year risk for the three risk categories. The CTS5 tool is 
intended for clinicians to determine the risk of late distant recurrence and may help in the 
decision-making process about extended endocrine therapy (www.cts5-calculator.com). 
Although the above studies have shown that the use of clinicopathological features are 
important, not just for prediction of late distant recurrences, it is widely accepted that these 
factors alone are inadequate for optimum patient management, especially as the 
management of breast cancer patients moves towards the era of personalised treatment. In 
the last two decades several genomic assays have been developed to improve 
prognostication of early breast cancer and several of them are recommended for clinical use 
by several expert panels. 
 
Genomic assays 
Oncotype Dx 
The Oncotype Dx Recurrence Score has been developed for women with ER-positive, node-
negative breast cancer and has been widely validated in several studies [2, 12-15]. This assay 
utilises expression measurements from 21 cancer-related genes to compute a recurrence 
score from 0 to 100, which can be categorized into low risk (<18), intermediate risk (18 to 30), 
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or high risk (≥31) groups. Several studies, including a meta-analysis of four prospective 
studies, have shown that the use of the Oncotype Recurrence Score leads to treatment 
changes in chemotherapy use, in particular in ER-positive, HER2-negative, and lymph node 
negative disease [16-18].  
In a comprehensive head-to-head comparison of several prognostic genomic assays [19], The 
Oncotype Dx Recurrence score was only significantly prognostic in women with ER-positive, 
lymph node negative disease for the first 5 years after diagnosis. For those with lymph-node 
positive disease or for the prediction of late distant recurrences, the Oncotype Dx Recurrence 
Score did not provide any substantial prognostic value when compared to Prosigna or 
EndoPredict. The prognostic value of the Oncotype Dx Recurrence Score has extensively been 
investigated [12, 20] and more recently the predictive value of the assay has been reported.  
The TAILORx study randomised women with ER-positive, HER2-negative, lymph-node 
negative disease and intermediate recurrence scores (11-25) to endocrine therapy alone or 
to endocrine therapy plus chemotherapy [21]. The results showed that women in this 
intermediate risk group by Oncotype did not benefit from additional chemotherapy 
compared to those that only received endocrine therapy, with very similar 9-year invasive 
disease-free survival. Looking at different sub-group analyses, the authors did not find any 
significant interaction between treatment and several prognostic clinical features, except for 
age, making it unclear whether younger women might still benefit from chemotherapy in the 
intermediate risk group. This finding is supported by data from the SOFT [22]  and TEXT [23] 
trials wherein premenopausal women at intermediate or high risk have substantial 
improvement in outcome with ovarian function suppression after chemotherapy. Of note, the 
ranges used to define the risk groups in the TAILORx study are different from those 
traditionally used (see above), and hence increasing the size of the intermediate risk group 
substantially. However, using traditional clinical parameters, most of these women would not 
have been regarded as having an intermediate risk of developing a recurrence and hence 
would not have been candidates for chemotherapy in the first place.  
To further evaluate the clinical utility of Oncotype Dx Recurrence Score for node-positive 
patients, the RXPONDER trial (SWOG S1007) enrolled ER-positive, HER2-negative patients 
with 1–3 involved regional lymph nodes and low-to-intermediate recurrence scores (≤25). 
Patients are being randomly allocated to endocrine therapy alone or to endocrine therapy 
plus chemotherapy. The results from this study are still outstanding. Results from a large 
prospectively designed registry study showed that women with ER-positive, HER2-negative, 
1-3 lymph node positive disease with a Recurrence score between 18-30 and who were 
treated with chemotherapy had a significantly lower recurrence rate compared to untreated 
patients [24]. 
Prosigna 
The Prosigna assay has been developed for postmenopausal women with ER-positive, lymph 
node-negative or node positive disease who were treated with tamoxifen [5]. Several 
validation studies have shown the prognostic utility of this assay for the prediction of early 
(years 0-5) [25] and late distant recurrences [26] and significantly distinct risk stratification 
for women with lymph-node negative and positive disease [19]. The Prosigna assay has 
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recently been further validated in a Danish cohort of postmenopausal women with lymph-
node negative and positive disease who have received 5 years of endocrine therapy [27]. In 
this population based cohort, the Prosigna assay identified 37% of patients with a one positive 
lymph node and 15% of patients with two positive nodes as low risk, with very favourable 
outcomes when treated with adjuvant endocrine therapy alone. This analysis did not include 
any women with a low risk of recurrence (node-negative, tumours smaller than 20mm, and 
grade 1 tumours) and the risk stratification observed here are different than those in 
validation studies from large clinical trials [25, 28]. The observational Oslo1 study furthermore 
confirmed that in particular the intrinsic Prosigna sub-types improve classification of patients 
with ER-positive, HER2-negative, and lymph node negative breast cancer into distinct risk 
groups [29]. The Prosigna provided substantial prognostic value for distant recurrence in a 
comparative analysis, classifying patients into distinct low, intermediate and high risk groups 
with significantly different 10-year outcomes [19]. 
The Prosigna assay was also investigated in premenopausal women of whom the majority had 
lymph-node positive disease and who received cyclophosphamide-based adjuvant 
chemotherapy [30].  The results showed that continuous Prosigna ROR score was prognostic 
in high-risk premenopausal women with breast cancer but no interaction with treatment was 
observed in the overall study population.  However, in a subset analysis, for women with ER-
positive, Her2-negative disease a significant benefit of chemotherapy was observed for those 
who had a high ROR score (high risk group > 40). Furthermore, a strongly significant 
interaction was observed between Prosigna intrinsic subtypes and chemotherapy use. 
Women with a basal-like or luminal B sub-type had a distinct benefit from cyclophosphamide-
based chemotherapy.  
The predictive ability of the Prosigna assay is currently being investigated in the OPTIMA trial 
[31]. Initial analysis of the preliminary OPTIMA trial [32] showed that the Prosigna assay was 
ranked highest in terms of research value and is therefore being investigated further in the 
full trial. 
EndoPredict 
The EndoPredict assay was developed in women with ER-positive, lymph node-negative or 
positive, and HER2-negative disease [6, 33]. It has been validated in postmenopausal women 
who received endocrine therapy for the prediction of early and late distant recurrences [34-
38] and in premenopausal women who received endocrine therapy plus chemotherapy [39]. 
It is one of the few genomic assays that has only two risk categories, with generally classifying 
more women into the high risk group, specifically in node-positive disease. However, the two 
risk groups should not be regarded as a disadvantage of the test, rather the opposite. There 
have been several observational and decision impact studies over the past year investigating 
the EndoPredict assay. In a small study of 120 patients, the impact of the EndoPredict on 
chemotherapy recommendations was investigated [40]. 35% of women classified as being 
high risk by the Nottingham Prognostic Index, and therefore candidates for chemotherapy, 
were classified into the low risk group by EndoPredict, indicating that the use of EndoPredict 
can reduce the need for adjuvant chemotherapy in women with ER-positive, HER2-negative 
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disease. Other decision impact studies have shown similar results where the use of the 
EndoPredict assay in the clinic reduced chemotherapy recommendations by 30-40% [41, 42].  
Other assays 
Other genomic assays, such as the Breast Cancer Index [7, 43], MammaPrint [3], Genomic 
Grade Index [4], have also been investigated for ER-positive breast cancer. Newer genomic 
assays that have reported the results over the past year include the OncoMasTR [44], the 
Curebest 95GC Breast assay [45], and a 95-gene assay [46]. The OncoMasTR incorporates 
three genes with clinical parameters (tumour size and nodal status) into the final assay. Initial 
validation has shown that OncoMasTR provides significant prognostic information for (late) 
distant recurrence and provides differential risk stratification (low versus high risk), in 
particular for node negative disease and to a lesser extent in those with lymph node positive 
disease [44]. The Curebest is a pure molecular assay and was validated for the prognostic 
performance for the prediction of early recurrence only (<5 years), with significant differential 
classification in to low and high risk groups [47]. An interesting study developing a novel 95 
gene assay using pathology samples from the TEAM trial has recently reported their results 
[46]. The final 95 gene test incorporates information on nodal status and stratifies patients 
into low and high risk groups, with significantly different 10-year distant recurrence risk. 
Although the assay needs to be further validated in an independent patient cohort, an exciting 
aspect of this assay is that they have identified several genes and pathways suitable for 
targeted therapies, indicating that the test might predict response to drug-specific 
chemotherapy [46]. 
 
Conclusion 
In summary, all validation studies for the Oncotype Dx Recurrence Score, Prosigna, and 
EndoPredict examined prognosis in prospective clinical trials in which at least one arm 
received a standard endocrine treatment and although the tumour blocks were tested 
retrospectively, the trials themselves were prospective in design and constitute level IB 
evidence for prognostic validity [48]. For patients with ER-positive disease who receive 
endocrine therapy alone, all three assays identify a low risk population with a favourable 
outcome at 5 or 10 years after diagnosis. A low risk assay test result is therefore actionable, 
and the decision to withhold chemotherapy is supported by this evidence. The same is true 
for categorisation into high risk groups by these tests, in particular by Prosigna and 
EndoPredict, where the addition of chemotherapy is warranted. Any information obtained 
from any of the genomic assays must still be interpreted in the context of clinicopathological 
features of the tumour. Several guidelines, including the American Society of Clinical 
Oncology working group [49], emphasise that the prognostic utility of these tests are to be 
interpreted with clinicopathological features. Although the Oncotype Dx Recurrence score 
has been most widely investigated and validated assay for ER-positive, HER2-negative, lymph 
node negative disease, newer second generation assays such as Prosigna and EndoPredict 
have significant advantages over Oncotype in terms of prognostic value for lymph-node 
positive disease, and in particular for the prediction of late distant recurrence. To determine 
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who is going to develop a late distant recurrence is an important clinical question and 
although none of the genomic assays was particularly trained to predict late recurrence, some 
of them have shown to accurately stratify patients into respective risk categories. Clinical 
parameters that are available to all clinicians have been shown to be of great importance for 
the prediction of late recurrences. Most guidelines now endorse genomic assays [49-52] in 
particular for lymph-node negative disease. When a decision is made about a genomic assay, 
it is important to use only one as risk group stratification between two tests are different 
when more than one test is used [53]. The identification of clinically useful markers for 
women with triple negative breast cancer is still one of the more important unsolved 
questions. Better progress has been made for premenopausal women although a specifically 
developed genomic assay for younger breast cancer patients still does not exist. However, 
several new technologies, including miRNA, circulating tumour DNA, RNA sequencing, may 
improve and extended the current prediction models. 
 
Key bullet points 
 Genomic assays help for the improvement of prognostication of ER-positive breast 
cancer. 
 Clinical parameters are still very important to determine prognosis and genomic 
assays should be used in conjunction with these features. 
 Chemotherapy effects need to be assessed in terms of absolute benefits and a 
genomic test that is highly prognostic for recurrence is therefore highly predictive of 
the absolute benefit of treatment.  
 Several studies have shown that chemotherapy benefit can be investigated in a non-
randomised fashion. 
 Several new technologies may improve and extended the current prediction models 
specifically for women with ER-negative disease. 
 
Acknowledgements 
None 
Financial support and sponsorship 
This work has been supported by Cancer Research UK. 
Conflicts of interest 
IS has received lecture fees from Myriad Genetics and Nanostring Technologies.  
9 
 
References 
1. Polyak, K., Heterogeneity in breast cancer. J Clin Invest, 2011. 121(10): p. 3786-8. 
2. Paik, S., et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative 
breast cancer. N Engl J Med, 2004. 351(27): p. 2817-26. 
3. Cardoso, F., et al., 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast 
Cancer. N Engl J Med, 2016. 375(8): p. 717-29. 
* Mammaprint showing its costeffectivenesss in clinical high risk patients to clinical assessment 
alone. 
4. Metzger Filho, O., et al., Genomic Grade Index: An important tool for assessing breast cancer 
tumor grade and prognosis. Crit Rev Oncol Hematol, 2011. 77(1): p. 20-9. 
5. Wallden, B., et al., Development and verification of the PAM50-based Prosigna breast cancer 
gene signature assay. BMC Med Genomics, 2015. 8: p. 54. 
6. Kronenwett, R., et al., Decentral gene expression analysis: analytical validation of the 
Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer, 2012. 12: p. 456. 
7. Sgroi, D.C., et al., Prediction of late distant recurrence in patients with oestrogen-receptor-
positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-
gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol, 2013. 
14(11): p. 1067-76. 
8. Sestak, I., et al., Markers for the identification of late breast cancer recurrence. Breast Cancer 
Res, 2015. 17: p. 10. 
9. Sestak, I., et al., Factors predicting late recurrence for estrogen receptor-positive breast cancer. 
J Natl Cancer Inst, 2013. 105(19): p. 1504-11. 
10. Pan, H., et al., 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy 
at 5 Years. N Engl J Med, 2017. 377(19): p. 1836-1846. 
** Results from Oxford overview showing that risk of late distant recurrence is strongly related to 
nodal status and tumour size, even in those with low risk tumours, 20-year risks are 10%. 
11. Dowsett, M., et al., Integration of Clinical Variables for the Prediction of Late Distant Recurrence 
in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine 
Therapy: CTS5. J Clin Oncol, 2018. 36(19): p. 1941-1948. 
** Results from the TransATAC and BIG 1-98 trials showing that combining clinical paramaters is 
highly prognostic for the prediction of late distant recurrence. 
12. Paik, S., et al., Gene expression and benefit of chemotherapy in women with node-negative, 
estrogen receptor-positive breast cancer. J Clin Oncol, 2006. 24(23): p. 3726-34. 
13. Sparano, J.A., et al., Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. 
N Engl J Med, 2015. 373(21): p. 2005-14. 
14. Sparano, J.A., et al., Development of the 21-gene assay and its application in clinical practice 
and clinical trials. J Clin Oncol, 2008. 26(5): p. 721-8. 
15. Dowsett, M., et al., Prediction of risk of distant recurrence using the 21-gene recurrence score 
in node-negative and node-positive postmenopausal patients with breast cancer treated with 
anastrozole or tamoxifen: a TransATAC study. J Clin Oncol, 2010. 28(11): p. 1829-34. 
16. Markopoulos, C., et al., Clinical evidence supporting genomic tests in early breast cancer: Do 
all genomic tests provide the same information? Eur J Surg Oncol, 2017. 43(5): p. 909-920. 
* Intersting overview comparing different genomic assays. 
17. Albanell, J., et al., Pooled analysis of prospective European studies assessing the impact of 
using the 21-gene Recurrence Score assay on clinical decision making in women with 
oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage 
breast cancer. Eur J Cancer, 2016. 66: p. 104-13. 
18. Rouzier, R., et al., Multigene assays and molecular markers in breast cancer: systematic review 
of health economic analyses. Breast Cancer Res Treat, 2013. 139(3): p. 621-37. 
19. Sestak, I., et al., Comparison of the Performance of 6 Prognostic Signatures for Estrogen 
Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA 
Oncol, 2018. 
** Intersting paper comparing several genomic assays in a head-to-head fashion in the 
TransATAC trial. 
20. Cuzick, J., et al., Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-
67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison 
10 
 
with the Genomic Health recurrence score in early breast cancer. J Clin Oncol, 2011. 29(32): 
p. 4273-8. 
21. Sparano, J.A., et al., Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast 
Cancer. N Engl J Med, 2018. 379(2): p. 111-121. 
** Results showing that women with intermediate Oncotype Recurrence Score do not benefit from 
adjuvant chemotherapy. 
22. Francis, P.A., et al., Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J 
Med, 2015. 372(5): p. 436-46. 
23. Pagani, O., et al., Adjuvant exemestane with ovarian suppression in premenopausal breast 
cancer. N Engl J Med, 2014. 371(2): p. 107-18. 
24. Stemmer, S.M., et al., Clinical outcomes in ER+ HER2 -node-positive breast cancer patients 
who were treated according to the Recurrence Score results: evidence from a large 
prospectively designed registry. NPJ Breast Cancer, 2017. 3: p. 32. 
25. Dowsett, M., et al., Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 
for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol, 2013. 31(22): p. 
2783-90. 
26. Sestak, I., et al., Prediction of late distant recurrence after 5 years of endocrine treatment: a 
combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and 
arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of 
recurrence score. J Clin Oncol, 2015. 33(8): p. 916-22. 
27. Laenkholm, A.V., et al., PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence 
in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of 
Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. J Clin Oncol, 2018. 
36(8): p. 735-740. 
28. Gnant, M., et al., Predicting distant recurrence in receptor-positive breast cancer patients with 
limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 
postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. 
Ann Oncol, 2014. 25(2): p. 339-45. 
29. Ohnstad, H.O., et al., Prognostic value of PAM50 and risk of recurrence score in patients with 
early-stage breast cancer with long-term follow-up. Breast Cancer Res, 2017. 19(1): p. 120. 
30. Jensen, M.B., et al., The Prosigna gene expression assay and responsiveness to adjuvant 
cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast 
cancer. Breast Cancer Res, 2018. 20(1): p. 79. 
* Results from Danish cohort showing that Prosigna is highly prognostic in premenopausal 
women. 
31. Bartlett, J., et al., Selecting breast cancer patients for chemotherapy: the opening of the UK 
OPTIMA trial. Clin Oncol (R Coll Radiol), 2013. 25(2): p. 109-16. 
32. Hall, P.S., et al., Value of Information Analysis of Multiparameter Tests for Chemotherapy in 
Early Breast Cancer: The OPTIMA Prelim Trial. Value Health, 2017. 20(10): p. 1311-1318. 
33. Denkert, C., et al., Decentral gene expression analysis for ER+/Her2- breast cancer: results of 
a proficiency testing program for the EndoPredict assay. Virchows Arch, 2012. 460(3): p. 251-
9. 
34. Buus, R., et al., Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score 
for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst, 2016. 
108(11). 
* Validation of the EndoPredict assay in the TransATAC cohort. 
35. Dubsky, P., et al., The EndoPredict score identifies late distant metastases in ER+/HER2- 
breast cancer patients. Cancer Res, 2012. 72(24 Supplemental): p. S4-3. 
36. Dubsky, P., et al., The EndoPredict score provides prognostic information on late distant 
metastases in ER+/HER2- breast cancer patients. Br J Cancer, 2013. 109(12): p. 2959-64. 
37. Dubsky, P., et al., EndoPredict improves the prognostic classification derived from common 
clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol, 2013. 24(3): 
p. 640-7. 
38. Filipits, M., et al., A new molecular predictor of distant recurrence in ER-positive, HER2-
negative breast cancer adds independent information to conventional clinical risk factors. Clin 
Cancer Res, 2011. 17(18): p. 6012-20. 
11 
 
39. Martin, M., et al., Clinical validation of the EndoPredict test in node-positive, chemotherapy-
treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer 
Res, 2014. 16(2): p. R38. 
40. Mokbel, K., et al., The Impact of EndoPredict Clinical Score on Chemotherapy 
Recommendations in Women with Invasive ER(+)/HER2(-) Breast Cancer Stratified as Having 
Moderate or Poor Prognosis by Nottingham Prognostic Index. Anticancer Res, 2018. 38(8): p. 
4747-4752. 
41. Fallowfield, L., et al., Enhancing decision-making about adjuvant chemotherapy in early breast 
cancer following EndoPredict testing. Psychooncology, 2018. 27(4): p. 1264-1269. 
* Analysis looking at the impact of EndoPredict in the decision-making process about 
chemotherapy across several UK hospitals. 
42. Ettl, J., et al., Decision impact and feasibility of different ASCO-recommended biomarkers in 
early breast cancer: Prospective comparison of molecular marker EndoPredict and protein 
marker uPA/PAI-1. PLoS One, 2017. 12(9): p. e0183917. 
43. Jerevall, P.L., et al., Prognostic utility of HOXB13:IL17BR and molecular grade index in early-
stage breast cancer patients from the Stockholm trial. Br J Cancer, 2011. 104(11): p. 1762-9. 
44. Sestak, I., et al., Evaluation of the OncoMasTR prognostic signature in postmenopausal women 
with primary ER-positive breast cancer. J Clin Oncol, 2018. 36((suppl; abstr 553)). 
45. Kinoshita, T., et al., The first report of multicenter validation study of 95-gene classifier, a multi-
gene prognostic assay of estrogen receptor positive and node negative breast cancer patients. 
Annals of Oncology, 2017. 28. 
46. Bayani, J., et al., Molecular stratification of early breast cancer identifies drug targets to drive 
stratified medicine. Npj Breast Cancer, 2017. 3. 
* Idebtification of a new prognostic genomic assay with additional potential to prioritise patients 
for treatment with targeted therapies. 
47. Naoi, Y., et al., Multi-gene classifiers for prediction of recurrence in breast cancer patients. 
Breast Cancer, 2016. 23(1): p. 12-8. 
48. Simon, R.M., et al., Use of archived specimens in evaluation of prognostic and predictive 
biomarkers. J Natl Cancer Inst, 2009. 101(21): p. 1446-52. 
49. Harris, L.N., et al., Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for 
Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology 
Clinical Practice Guideline. J Clin Oncol, 2016. 34(10): p. 1134-50. 
50. Duffy, M.J., et al., Clinical use of biomarkers in breast cancer: Updated guidelines from the 
European Group on Tumor Markers (EGTM). Eur J Cancer, 2017. 75: p. 284-298. 
51. Senkus, E., et al., Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up. Ann Oncol, 2015. 26 Suppl 5: p. v8-30. 
52. Curigliano, G., et al., De-escalating and escalating treatments for early-stage breast cancer: 
the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early 
Breast Cancer 2017. Ann Oncol, 2017. 28(8): p. 1700-1712. 
53. Gyorffy, B., et al., Multigene prognostic tests in breast cancer: past, present, future. Breast 
Cancer Res, 2015. 17: p. 11. 
 
 
